Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP

Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch of Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials. Glenmark's Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Naropin® Injection, 40 mg/20 mL (2 mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL), of Fresenius Kabi USA, LLC NDA - 020533. Glenmark will begin distribution in November 2025.

According to IQVIA® sales data for the 12-month period ending August 2025, the Naropin® Injection, 40 mg/20 mL (2 mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) market achieved annual sales of approximately $20.9 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "We are pleased to announce the launch of Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials. This launch represents another important addition to Glenmark's expanding injectable portfolio and reinforces our dedication to bring quality and affordable alternatives to market for patients in need."

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 1855.70 as compared to the previous close of Rs. 1852.85. The total number of shares traded during the day was 3615 in over 315 trades.

The stock hit an intraday high of Rs. 1861.30 and intraday low of 1845.50. The net turnover during the day was Rs. 6699347.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 USA Launch RopivacaineHydrochloride Injection